No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: Results of a multicenter study of somatosensory and visual evoked potentials

Epilepsia

Volumn 38, Issue 3, 1997, Pages 301-308

  Mauguiere F ^a   Chauvel, P ^b   Dewailly, J ^o   Dousse, N ^b   Garrel, S ^c   Guieu, J D ^d   Revol, M ^e   Farnarier, G ^f   Baldy Moulinier, M ^g   Weber, M ^h   Baulac, M ⁱ   Gueguen, B ⁱ   Gil, R ^j   Michel, D ^k   Marescaux, Ch ^l   Clanet, M ^m   Autret, A ⁿ  

^a HÔPITAL NEUROLOGIQUE   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c Marion Merrell   (France)

^d Tour Roussel Hoechst   (France)

^e Marion Merrell   (France)

^f Marion Merrell   (France)

^g Marion Merrell   (France)

^h Tour Roussel Hoechst   (France)

ⁱ Marion Merrell   (France)

^j Tour Roussel Hoechst   (France)

^k Marion Merrell   (France)

^l SANOFI   (France)

^m Marion Merrell   (France)

ⁿ Marion Merrell   (France)

^o NONE

more..

Author keywords

Antiepileptic drug therapy; Central conduction; Intramyelinic edema; Somatosensory evoked potential; Vigabatrin; Visual evoked potential

Indexed keywords

VIGABATRIN;

ADOLESCENT; ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; EPILEPSY; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; EVOKED POTENTIALS, SOMATOSENSORY; EVOKED POTENTIALS, VISUAL; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MEDIAN NERVE; MIDDLE AGED; NEURAL CONDUCTION; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIGABATRIN;

EID: 1842409548     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb01121.x     Document Type: Article

References (23)

1. Jung MJ, Lippert B, Metcalf BW, Schechter PJ. Gamma-vinyl GABA (4-amino-hex-5-enolic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 1977;29:797-802.
2. Schechter PJ, Hanke NJF, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology 1984;34:182-6.
3. Halonen T, Lehtinen M, Pitkänen A, Ylinen A, Riekkinen PJ. Inhibitory and excitatory amino acids in CSF of patients suffering from complex partial seizures: a long-term study. Epilepsy Res 1989;27:43S-5S.
4. Lippert B, Metcalf BW, Resvick R. Enzyme-activated irreversible inhibition of rat and mouse brain 4-aminobutyric acid alpha-ketoglutarate transaminase by 5-fluoro-4-oxo-pentanoic acid. Biochem Biophys Res Commun 1982;108:146-52.
5. Loiseau P, Hardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP. Double-blind placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug resistant epilepsy. Epilepsia 1986;27:115-20.
6. Mumford JP, Dam M. Meta-analysis of European placebo-controlled studies of vigabatrin in drug-resistant epilepsy. Br J Clin Pharmacol 1989;27(suppl 1):101S-7S.
7. Hammond EJ, Wilder BJ. Gamma-vinyl GABA: a new antiepileptic drug. Clin Neuropharmatol 1985;8:1-12.
8. Arezzo JC, Schroeder CE, Litwak MS, Steward DL. Effects of vigabatrin on evoked potentials in dogs. Br J Clin Pharmacol 1989;27fsuppl 1):53S-60S.
9. Weiss KL, Schroeder CE, Kashin S, et al. Vigabatrin-induced intramyelinic oedema II: effects on MRI in dogs. Neurology 1991;41(suppl 1):331.
10. Cosi V, Callieco R, Galimberti CA, et al. Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 1989;27:61S-8S.
11. Hammond EJ, Rangel RJ, Wilder BJ. Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 1988;42(suppl 61):16-23.
12. Mervaala E, Partanen J, Nousiainen U, Sivenius J, Riekkinen P. Electrophysiologic effects of γ-vinyl GABA and carbamazepine. Epilepsia 1989;30:189-93.
13. Ylinen A, Sivenius J, Pitkanen A, et al. γ-Vinyl GABA (vigabatrin) in epilepsy: clinical, neurochemical, and neurophysiologic monitoring in epileptic patients. Epilepsia 1992;33(suppl 5):917-22.
14. Liègeois-Chauvel C, marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P. Effects of long-term vigabatrin on somatosensory evoked potentials in epileptic patients. Br J Clin Pharmacol 1989;27(suppl 1):69S-72S.
15. Mikkelsen M, Dam M, Gram L, Matthews J, Mumford JP. Vigabatrin in drug-resistant epilepsy: ten years' experience [Abstract]. Epilepsia 1991;32(suppl 1):10-1.
16. Reynolds EH, Ring HA, Fan IN, Heller AJ, Elwes RD. Open, double-blind and long-term study of vigabatrin in chronic epilepsy. Epilepsia 1991;32:530-8.
17. Mauguière F, Cooper R, Holder GE, Luxon LM, Murray NMF. Evoked potentials: normal findings by modality. In: Binnie C, Cooper R, Fowler C, Mauguière F, Osselton J, Prior P, eds. Clinical neurophysiohgy, EMG, nerve conduction and evoked potentials. London: Butterworth, 1995:364-430.
18. Green JB, Walcoff MR, Lucke JF. Phenytoin prolongs far-field somatosensory and auditory evoked potential interpeak latencies. Neurology 1982;32:85-8.
19. Mervaala E, Keranen T, Tiihonen P, Riekkinen P. The effects of carbamazepine and sodium valproate on SEPs and BAEPs. Electroencephalogr Clin Neurophysiol 1987;68:475-78.
20. Zgorzaiewicz M, Galas-Zgorzalewicz B, Szwacki W. Auditory evoked potentials during long-term antiepileptic treatment in drugresistant childhood partial epilepsy: the effect of carbamazepine and add-on vigabatrin. Epilepsia 1995;36(suppl 3):S87.
21. Sommerville KW, Arezzo JC. Evoked potentials in a multicenter trial of vigabatrin in focal epilepsy, Epilepsia 1993;34(suppl 6):123-4.
22. Fisher RS, Kerrigan JF. Vigabatrin toxicity. In: Levy R, Mattson PH, Meldrum BS, eds. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995:931-9.
23. Mervaala E, Kälviäinen R, Könönen M, et al. Vigabatrin and carbamazepine monotherapy do not impair cognitive functions in event-related potentials. Epilepsia 1993;34(suppl 6):95.